What is Acadia Pharmaceuticals?
Acadia Pharmaceuticals is a neuroscience therapeutics company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Neuroscience therapeutics
- Headquarters
- San Diego, CA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: ACAD
What is Acadia Pharmaceuticals?
Acadia Pharmaceuticals is a neuroscience therapeutics company headquartered in San Diego, CA.
Acadia Pharmaceuticals operates in neuroscience therapeutics and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around NUPLAZID, DAYBUE, Neuroscience pipeline, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Acadia Pharmaceuticals is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: ACAD, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Acadia Pharmaceuticals offer?
Acadia Pharmaceuticals's profile centers on NUPLAZID, DAYBUE, Neuroscience pipeline, Commercial neurology.
- NUPLAZID· Neuroscience therapeutics
- DAYBUE· Neuroscience therapeutics
- Neuroscience pipeline· Neuroscience therapeutics
- Commercial neurology· Neuroscience therapeutics
- Rare disease· Neuroscience therapeutics
- Clinical programs· Neuroscience therapeutics
How does Acadia Pharmaceuticals make money?
Acadia Pharmaceuticals makes money through commercial activity tied to neuroscience therapeutics.
Acadia Pharmaceuticals monetizes through the commercial model common to neuroscience therapeutics: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Acadia Pharmaceuticals?
Acadia Pharmaceuticals's named executives should be verified on the official leadership or investor-relations page before outreach.
- Acadia Pharmaceuticals executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Acadia Pharmaceuticals finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Acadia Pharmaceuticals technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Acadia Pharmaceuticals's leadership?
Acadia Pharmaceuticals should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.acadia.com- Acadia Pharmaceuticals investor relationsInvestor relations / corporate contactcontact via https://www.acadia.com
- Acadia Pharmaceuticals sales or partnershipsCommercial contact routecontact via https://www.acadia.com
- Acadia Pharmaceuticals media relationsMedia or communications contact routecontact via https://www.acadia.com
How is Acadia Pharmaceuticals funded?
Acadia Pharmaceuticals's current status is Public company; Nasdaq: ACAD.
Acadia Pharmaceuticals's current capital profile is best understood through its current status: Public company; Nasdaq: ACAD. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Acadia Pharmaceuticals get here?
Acadia Pharmaceuticals's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingAcadia Pharmaceuticals is foundedThe company begins building in neuroscience therapeutics.
- Scale-upCommercial footprint expandsAcadia Pharmaceuticals broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: ACADOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Acadia Pharmaceuticals's competitors?
Acadia Pharmaceuticals competes with larger platform incumbents and focused specialists in neuroscience therapeutics.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Acadia Pharmaceuticals — frequently asked questions
